MONDAY, June 25 (HealthDay News) -- Two new non-invasive devices show promise as accurate indicators of blood glucose levels, according to two studies presented this week at the annual meeting of the American Diabetes Association in Chicago.
Robert Gabbay, M.D., of the Pennsylvania State University Medical Center in Hershey, Penn., and colleagues tested an optical coherence tomography device -- GlucoLight -- on 27 type 1 and type 2 diabetics who received a 50-gram carbohydrate load on day one. Thirteen of the subjects also received a 25-30 gram carbohydrate load on days two through five. The researchers found that the Pearson correlation coefficient comparing optical coherence tomography with capillary blood glucose was 0.88.
"The device maintained calibration over four days with no adverse side effects," Gabbay and his colleagues conclude. "Future efforts will evaluate the accuracy of the system in the hypoglycemic range."
Orna Amir, Ph.D., of OrSense Ltd., in Rehovot, Israel, and colleagues tested a device based on red near-infrared occlusion spectroscopy technology -- the NBM-100 -- on seven diabetics. They found that the Pearson correlation coefficient was 0.9.
"The NBM is currently under evaluation in broader clinical settings," the authors note.
Abstract - Gabbay
Abstract - Amir
